There is a high heterogeneity in 2-year OS rate among newly diagnosed IDH-mutated AML patients receiving combination therapy with IDH inhibitors (I2 = 85%), which derives from the different drugs combined with IDH inhibitors (azacitidine: 2 cohorts, intensive chemotherapy: 1 cohort). This evidence concerns the gene IDH1 and acute myeloid leukemia.